Physician profile
Lambert Chee
NPI 1154329282
$398.80
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $78.57.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $126.62 | 2019 | |
| Gilead Sciences, INC. | $106.34 | 2019 | |
| Pfizer INC. | $87.27 | 2019 | |
| Ethicon US, LLC | $66.67 | 2020 | |
| Davol INC. | $11.90 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lambert Chee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.